Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 in patients with hematologic malignancies and renal impairment
NCT03555955Phase 1Completed
- Sponsor
- Jazz Pharmaceuticals plc
- Start
- Nov 2018
- Primary completion
- May 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of cytarabine in hematologic malignancy, acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and 1 more (3 arms), sponsored by Jazz Pharmaceuticals plc. Primary endpoint: Pharmacokinetics of CPX-351. Started Nov 2018; status: completed.
02
Drugs
cytarabine
03
Conditions
hematologic malignancyacute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03555955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03555955.